Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 512 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Genotyping Clear all
Recruiting Phase 1 Interventional

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

NCT04361708
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma
Interventions
Oxaliplatin, Docetaxel, Leucovorin, Irinotecan, 5-Fluorouracil
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 25, 2026, 4:53 AM EDT
Not listed Not applicable Interventional

Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing

NCT00484640
View directory record Official record
Conditions
Atrial Fibrillation, Deep Venous Thrombosis, Heart Valve Replacement, Pulmonary Embolism
Interventions
Coumadin
Drug
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
40 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Madison, Wisconsin • Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2007 · Synced Oct 25, 2026, 4:53 AM EDT
Completed No phase listed Observational

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

NCT00001452
View directory record Official record
Conditions
Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease, Peutz-Jeghers Syndrome
Interventions
oCRH
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 70 Years
Enrollment
1,387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 4:53 AM EDT
Completed No phase listed Observational

Genetic Analysis of Oculocerebrorenal Syndrome of Lowe

NCT00359515
View directory record Official record
Conditions
Lowe Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 4:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions

NCT00758108
View directory record Official record
Conditions
WAGR Syndrome, Wilm's Tumor, Aniridia, Urogenital Abnormalities, Mental Retardation
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 99 Years
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 25, 2026, 4:53 AM EDT
Terminated No phase listed Observational

SPECT Imaging of DAT Genotype

NCT01492322
View directory record Official record
Conditions
Nicotine Withdrawal
Interventions
TRODAT
Radiation
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

NCT02226549
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF, VDV, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 25, 2026, 4:53 AM EDT
Completed No phase listed Observational

Primary Hyperoxaluria Mutation Genotyping/Phenotyping

NCT02340689
View directory record Official record
Conditions
Primary Hyperoxaluria
Interventions
Genetic Analysis
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Day and older
Enrollment
1,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 25, 2026, 4:53 AM EDT
Withdrawn No phase listed Observational

A Study of the Natural Course of SURF1 Deficiency

NCT05277363
View directory record Official record
Conditions
Leigh Syndrome
Interventions
None (Observational study)
Other
Lead sponsor
Taysha Gene Therapies, Inc.
Industry
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

NCT03212521
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

NCT01625338
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF, RBV, Peg-IFN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
67
States / cities
Birmingham, Alabama • Bakersfield, California • Colton, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Oct 25, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia

NCT04980638
View directory record Official record
Conditions
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Interventions
ER004
Biological
Lead sponsor
EspeRare Foundation
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 25, 2026, 4:53 AM EDT
Completed No phase listed Observational

Gene First Approach to Connective Tissue Disease

NCT04664478
View directory record Official record
Conditions
Abnormal Elastogenesis, Vascular Diseases, Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Not applicable Interventional

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

NCT02098616
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV
Drug
Lead sponsor
Timothy Morgan, MD
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

NCT01247194
View directory record Official record
Conditions
Chronic Genotype 1 Hepatitis C Virus Infection
Interventions
PPI-461, Placebo
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

NCT01628094
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
RO5024048, RO5190591, RO5466731, ribavirin [Copegus], ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
La Jolla, California • Englewood, Colorado • South Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 25, 2026, 4:53 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Phenotype, Genotype & Biomarkers in ALS and Related Disorders

NCT02327845
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia, Progressive Muscular Atrophy, Multisystem Proteinopathy
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
Not listed
Enrollment
708 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2031
U.S. locations
13
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 25, 2026, 4:53 AM EDT
Completed No phase listed Observational

A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART

NCT00000874
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
24
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sensitive Periods in Early Flavor Learning

NCT00994747
View directory record Official record
Conditions
Healthy
Interventions
Nutramigen (Flavor and Type of Infant Formula), Enfamil, milk-based formula
Other
Lead sponsor
Monell Chemical Senses Center
Other
Eligibility
2 Weeks to 4 Weeks
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype

NCT04901715
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
Albuterol, Technetium99m - Sulfur Colloid (Tc99m-SC)
Drug · Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 90 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 25, 2026, 4:53 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype

NCT02564692
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
Banner Health
Other
Eligibility
50 Years to 90 Years
Enrollment
500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

NCT01958281
View directory record Official record
Conditions
HCV Infection
Interventions
SOF, RBV, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
7
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

NCT01278134
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
La Jolla, California • Sacramento, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

NCT00457821
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor 25 mg/75 mg, Ivacaftor 75 mg/150 mg, Ivacaftor 150 mg or 250 mg, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 25, 2026, 4:53 AM EDT